指南与共识甲状腺与颈部外科

甲状腺腺叶切除治疗分化型甲状腺癌:患者能否避免术后甲状腺激素补充并符合ATA指南?

Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?
指南 / 共识 · Surgery · 2017-11-07

该回顾性研究纳入555例连续行甲状腺腺叶切除术的患者,评估术后未补充甲状腺激素时促甲状腺激素(TSH)能否维持<2 mIU/L。结果显示,术前未服药的478例中,一年内350例(73%)TSH>2 mIU/L,提示多数患者需补充激素以符合ATA指南。

要点

  • 甲状腺腺叶切除后多数患者需激素补充以维持TSH<2 mIU/L。
  • 术前未服药的478例中,73%在一年内TSH>2 mIU/L。
  • 应向患者说明避免终身激素补充的获益可能有限。

核心结论

  • 为符合ATA指南对分化型甲状腺癌低危患者TSH<2 mIU/L的要求,多数行甲状腺腺叶切除术的患者可能需要补充甲状腺激素。

研究设计与样本

  • 回顾性研究,连续纳入555例接受甲状腺腺叶切除术的患者。
  • 记录术前、术后7-10天及术后2-12个月的TSH水平和甲状腺激素补充情况。

主要发现

  • 555例中478例(86%)术前未服用甲状腺激素。
  • 478例中394例(82%)有术后7-10天TSH数据,其中218例(55%)TSH>2 mIU/L。
  • 术后2-12个月,225例仍未补充激素的患者中132例(59%)TSH升至>2 mIU/L。
  • 478例中350例(73%)在术后一年内TSH>2 mIU/L。

关键数值与推荐

  • ATA指南推荐低危分化型甲状腺癌患者术后维持TSH<2 mIU/L。
  • ATA指南推荐甲状腺腺叶切除可作为低危分化型甲状腺癌的替代选择。

临床怎么用

  • 向行甲状腺腺叶切除术的患者说明,为符合ATA指南,多数人可能需要补充甲状腺激素以维持TSH<2 mIU/L。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American Thyroid Association recommended thyroid lobectomy as an alternative for low-risk differentiated thyroid cancer. One hypothetical benefit includes avoiding lifelong thyroid hormone supplementation; however, guidelines recommend maintaining the thyroid-stimulating hormone <2 mIU/L postoperatively in low-risk patients. Our hypothesis is that most patients will require hormone supplementation to maintain thyroid-stimulating hormone <2 mIU/L, minimizing this advantage of lobectomy. The goal of this study is to determine how often patients have thyroid-stimulating hormone <2 mIU/L after lobectomy without thyroid hormone supplementation. METHODS: A retrospective review of 555 consecutive patients who underwent thyroid lobectomy was performed. Thyroid hormone supplementation was documented, along with thyroid-stimulating hormone levels preoperatively, 7 to 10 days, and 2 to 12 months postoperatively. RESULTS: In the study, 478/555 (86%) patients did not take thyroid hormone before thyroidectomy; 394/478 (82%) had thyroid-stimulating hormone levels available at 7 to 10 days postoperatively, and of these, 218 (55%) had thyroid-stimulating hormone >2 mIU/L. From 2 to 12 months postoperatively, of the 225 patients who continued to remain off thyroid hormone supplementation, 132 (59%) experienced a thyroid-stimulating hormone increase to >2 mIU/L; therefore, 350/478 (73%) patients after thyroid lobectomy had thyroid-stimulating hormone levels >2 mIU/L within a year. CONCLUSION: It is important to counsel patients that to be compliant with the American Thyroid Association guidelines for differentiated thyroid cancer, the majority of patients undergoing thyroid lobectomy may require thyroid hormone supplementation to maintain a thyroid-stimulating hormone level <2 m IU/L.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Cox C, Bosley M, Southerland LB, et al. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? Surgery. 2017. PMID: 29122328. doi:10.1016/j.surg.2017.04.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。